Episode #6: This Startup Is Changing the Way We Detect Cervical Cancer

Episode #6: This Startup Is Changing the Way We Detect Cervical Cancer

Author: by FemmeHealth Alliance April 24, 2025 Duration: 33:33

A few weeks ago, Ronald Vos and Nutte van Belzen, the founders of CC Diagnostics were at a major European medical congress when they were approached by a woman who didn’t work in science or medicine. She had bought an expensive delegate ticket, not to participate in the conference, but to seek help.

She had advanced cervical cancer. And she came in the hope that someone…anyone, at this gathering of gynaecologists and scientists might listen to her story and offer a lifeline.

We hope all those cases can be prevented,” co-founder Nutte van Belzen reflects.

That moment captures exactly why this episode matters.

Only 15% of women participate in cervical screenings, despite the fact that cervical cancer is entirely preventable through early detection and vaccination. The problem? Existing methods are invasive, uncomfortable, and all too easy to avoid until it’s too late.

In this conversation, the founders of CC Diagnostics share their journey: the personal experience and passion that fuels their mission, the technology they are building to make self-sampling accessible, and their vision for a world where diagnostics are not a privilege, but a right.

We also dive into:

* The overlooked challenges of building a diagnostics company.

* Why many investors hesitate and why that needs to change.

* Their roadmap for global access, including a pricing model for low- and middle-income countries (LMICs).

This isn’t just a conversation about tech or start-ups.

It’s about the human stories that push innovation forward, and the urgent need to act before another woman buys a ticket to beg for care.

🎧 Watch the full episode for a powerful and personal look at how we can, and must, do better in women’s health.

CC Diagnostics

CC Diagnostics (Netherlands) offers a clinically validated screening test, significantly improving cervical cancer detection rates to 97% (vs current market benchmark of 76%). Our product offers a 6x reduction in time per test for the diagnostic labs, dramatically reducing costs and improving efficiency. Our Methica test technology enables screening from home (with self-sampled material), unlocking a broader €5.5Bn screening market worldwide. We achieved commercial progress, with the first 2 international orders from leading CLIA labs in the US and UK.

CC Diagnostics (Netherlands)



Get full access to The Billion Dollar Blindspot at blog.billiondollarblindspot.com/subscribe

There's a vast, often overlooked frontier in business and innovation, and Blindspot Capital is mapping its terrain. This podcast digs into the ideas, trends, and tangible investment potential shaping the future of women's health, a sector that has historically been underfunded and underserved. Each episode moves beyond surface-level discussions to examine the systemic gaps and the consequential opportunities they create. You'll hear from founders, investors, researchers, and thinkers who are actively building and funding solutions in this space, sharing their on-the-ground experiences and hard-won insights. The conversations are grounded in the reality of entrepreneurship and market dynamics, exploring not just the "why" but the "how"-how new technologies are being applied, how businesses are scaling, and how capital can be deployed to generate both impact and returns. Tune in for a clear-eyed look at an area ripe for transformation, where understanding the blind spot isn't just about awareness, but about seeing a path forward for savvy builders and backers alike. This isn't a niche side conversation; it's a central dialogue about the next wave of growth in healthcare and technology, delivered through a podcast dedicated to substantive, forward-thinking analysis.
Author: Language: English Episodes: 18

Blindspot Capital
Podcast Episodes
The Menopause Information Crisis [not-audio_url] [/not-audio_url]

Duration: 31:16
Some markets follow a familiar script: a need emerges, founders respond, capital flows, and eventually, the sector matures. But women’s health doesn’t work like that.In a recent episode of Blindspot Capital, I sat down w…
Building FemTech Infrastructure in Asia [not-audio_url] [/not-audio_url]

Duration: 39:33
Some markets follow this script: A need appears. Entrepreneurs respond. Capital flows in. Eventually, the sector matures and innovation accelerates. But some markets don’t follow that script.In a recent episode of Blinds…
Why It Takes Years to Build in Women’s Health [not-audio_url] [/not-audio_url]

Duration: 34:44
Most innovation stories are told as clean upward lines. A founder has an idea. Investors come in. The product launches. Growth follows. Eventually there is an acquisition or an IPO, and the story looks inevitable in hind…
Why Women’s Heart Disease Is Still Misdiagnosed [not-audio_url] [/not-audio_url]

Duration: 34:58
In this episode of Blindspot Capital, Maryann sits down with Professor Angela Maas (cardiologist and pioneer of sex- and gender-specific cardiology) to unpack why women’s heart disease is still misunderstood and what med…
Tough Love for Women’s Health Founders [not-audio_url] [/not-audio_url]

Duration: 26:51
In this episode of Blindspot Capital, Maryann sits down with Lisa Suennen - longtime healthcare investor, founder of the Venture Valkyrie blog, and Managing Partner of the Go Red for Women Venture Fund to unpack one of t…
The Silent Ban: How Social Media Is Censoring Women’s Health [not-audio_url] [/not-audio_url]

Duration: 25:58
In this episode of Blindspot Capital, Maryann sits down with Anna O’Sullivan, co-founder of censhership.co.uk and FutureFemHealth, to unpack a deeply underrecognized systemic bias: the routine censorship of women’s healt…
Why Most Digital Health Startups Will Fail [not-audio_url] [/not-audio_url]

Duration: 30:18
Half the headlines in healthcare are hype. But what if we stopped chasing the next shiny thing and started fixing the fundamentals?In this episode of Blindspot Capital, I sit down with Sergei Polevikov, mathematician, in…